Glaucoma performance stabilized after lapping 2025 regulatory headwinds that restricted multiple MIGS procedures in ...

Sight Sciences (NASDAQ:SGHT) reported fourth-quarter 2025 results highlighting growth in both its interventional glaucoma and ...

Thank you for participating in today's call. Presenting today are Sight Sciences Co-Founder and Chief Executive Officer, Paul Badawi; and Chief Financial Officer, Jim Rodberg. Also in attendance is ...

Q4 2025 earnings call recap: 2026 revenue guidance, TearCare reimbursement milestone, OMNI growth outlook, margins and risks—read now.

Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2025 Earnings Call Transcript March 4, 2026 Sight Sciences, Inc. beats earnings expectations. Reported EPS is $-0.07841, expectations were $-0.15. Operator: Good ...

The risk for endophthalmitis after glaucoma drainage rises for up to 5 years and is much higher than that for a ...

A population study of California Medicare patients found that high air pollution levels correlated with the risk for failure of incisional glaucoma surgery.

A comanagement program at UCSF in which patients saw glaucoma-trained optometrists and had access to glaucoma specialists showed promising outcomes, according to a study published in Ophthalmology ...

Glaucoma is a leading cause of irreversible blindness worldwide and often goes undiagnosed until vision loss is advanced. Population-wide screening has long been considered impractical, but recent ...

Glaucoma is likely to be treated when IOP reaches 22 mm Hg, but research shows that risk consistently increases even at lower IOP levels, according to a study published in JAMA Ophthalmology.“In ...

A 1:1 randomized clinical trial compared personalized coaching plus electronic adherence monitoring against standard mailed education, with both groups continuing usual glaucoma care. Participants ...

A Support, Educate, Empower (SEE) glaucoma coaching program improves medication adherence compared with standard written education, according to a study published online Feb. 26 in JAMA Ophthalmology.